Marcia Frellick

1 week ago | oncologynewscentral.com | Marcia Frellick

Academic medical centers’ policies and expectations are widely thought to be contributing to an unprecedented wave of oncologist faculty leaving or planning to leave their institutions. In an effort to boost retention by strengthening career and personal satisfaction, the American Society of Clinical Oncology (ASCO) has developed eight new recommendations for academic institutions, which were recently published in the Journal of Clinical Oncology.

2 weeks ago | oncologynewscentral.com | Marcia Frellick

More than half of international medical graduates (IMGs) and Puerto Rican medical graduates (PRMGs) report facing racial/ethnic, sex, or language discrimination during oncology training and while in independent practice, according to findings from a cross-sectional survey recently published in JCO Global Oncology. An online survey was completed by a total of 362 participants, 97 of whom were in oncology.

2 weeks ago | medscape.com | Marcia Frellick

CHICAGO — The acquisition of cardiovascular practices by private equity firms has ballooned in recent years. Of the 342 cardiology clinics that have been acquired in the past decade, more than 94% occurred from 2021 to 2023. Cardiology is rather newto theprivate equity space compared with specialties such as orthopedics, ophthalmology, and dermatology, speakers reported during a forum at the American College of Cardiology (ACC) Scientific Session 2025.

3 weeks ago | medscape.com | Marcia Frellick

Restoring optimal functioning after pediatric concussion may take longer than conventionally thought — at least 3 months, especially for girls — when several outcome domains are part of the assessment, according to a new study. Concussion studies tend to focus on symptoms alone, but that approach might miss factors such as how patients are functioning in school or how they feel emotionally, lead author Miriam H.

3 weeks ago | oncologynewscentral.com | Youssef Rddad |Ryan Syrek |Marcia Frellick

In March, the U.S. Food and Drug Administration (FDA) granted designations to several key oncology drugs for lung, blood, and pancreatic cancers, among others. Bexmarilimab for Myelodysplastic SyndromesOn March 3, Faron Pharmaceuticals announced that the FDA granted orphan drug designation to bexmarilimab, an investigational immunotherapy, for the treatment of patients with myelodysplastic syndromes (MDS).